key: cord-0836813-zxc93z8w
authors: Hosoda, Tomohiro; Orikasa, Hideki
title: A fatal case of extensive gastrointestinal necrosis due to portal and mesenteric vein thrombosis in the post-acute phase of COVID-19
date: 2021-10-21
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.10.015
sha: c8ae5fe81582d985d2164cadee45c353727c8d7a
doc_id: 836813
cord_uid: zxc93z8w

Portal vein thrombosis (PVT) is considered a relatively rare thrombotic complication in coronavirus disease 2019 (COVID-19). Most reported cases of PVT develop within 2 weeks from COVID-19 onset. We report a fatal case of extensive gastrointestinal necrosis due to portal and mesenteric vein thrombosis approximately 6 weeks after the onset of critical COVID-19. Excessive elevation of his plasma D-dimer level had continued for weeks during the hospitalization contrary with improvement of respiratory failure. Thrombotic complication should be cautiously paid attention even in the post-acute phase of COVID-19, especially in patients with persistent elevation of plasma D-dimer level.

Thrombosis complicated with coronavirus disease 2019 (COVID-19) through vascular endothelial damage is associated with poor prognosis, especially in patients requiring intensive care unit (ICU) admission [1] . Pulmonary thrombosis is the most common venous thrombotic event experienced by COVID-19 patients. However, portal vein thrombosis (PVT) has rarely been reported as a thrombotic event with COVID-19 [1, 2] . Generally, the fatality rate is 50 to 70% for patients who develop intestinal infarction and extensive peritonitis induced by acute PVT with portal hypertension [3, 4] . The anticoagulant therapy for PVT is recommended to prevent intestinal infarction due to portal vein hypertension [4] .

Thrombotic events secondary to COVID-19 are usually developed within 2 weeks from ICU admission [1] . However, with a case report of late pulmonary embolism after COVID-19 pneumonia despite adequate anticoagulant therapy during the acute phase [5] , the duration of high-risk period to develop thrombotic events after recovery from COVID-19 remains unknown. Herein, we report a fatal case of extensive gastrointestinal necrosis due to portal and mesenteric vein thrombosis in the post-acute phase of COVID-19.

J o u r n a l P r e -p r o o f Case An 82-year-old Japanese man with a 3-day history of fever and fatigue was transferred to our hospital for the treatment of COVID-19. His medical history included coronary artery disease treated with aspirin and nicorandil, diabetes, and hypertension. He received favipiravir and subcutaneous unfractionated heparin (5000 units every 12 hours) for prophylaxis against deep vein thrombosis from the day of admission. On day 7 after disease onset, he developed acute respiratory distress syndrome and was admitted to the ICU for invasive mechanical ventilation. He received dexamethasone (6 mg per day). On the 17th day after disease onset, the negative result of real-time reverse transcription polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 was obtained four times from the nasopharyngeal sample. Temporary hemodynamic support with vasopressor was required for managing septic shock due to ventilator-associated pneumonia from days 18 to 26. Aspirin and subcutaneous unfractionated heparin were discontinued because of advancing anemia due to hemorrhage from the oral mucosa on days 22 and 28, respectively, although the patient's D-dimer level was consistently higher than 20 µg/mL from day 20. He was patients, especially in patients with hemorrhagic complication such as the present case [16] . Behnood B et al. have recommended extended prophylaxis for up to 45 days to prevent thrombotic events, especially in high-risk patients (e.g., reduced mobility, elevated D-dimer level) [17] . Some reports have recommended the D-dimer-drivenanticoagulation strategy to improve the outcome of hospitalized COVID-19 patients [18, 19] . According to a questionnaire-based survey in Japan, some clinicians have decided to initiate and discontinue anticoagulant therapy depending on the COVID-19 patients' plasma D-dimer level [20] . For the present case, we may have prevented the fatal portal 

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Portal vein thrombosis

Portal vein thrombosis

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment

COVID-19 as a novel etiology of portal vein thrombosis: change in the current management concepts

Spontaneous portomesenteric thrombosis in a non-cirrhotic patient with SARS-CoV-2 infection

Acute portal vein thrombosis secondary to COVID-19: a case report

Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation

Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations

Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients

Dynamic relationship between D-dimer and COVID-19 severity

Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19

D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis

Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020